MCL Literature Feed
137 papers on mantle cell lymphoma from PubMed. Updated daily.
An AI model using ensemble convolutional neural networks distinguished MCL from CLL and FL on pathology images with 99% accuracy, offering a potential tool for automated histopathological diagnosis.
This multi-modal single-cell atlas of the human tonsil provides a high-resolution map of normal B-cell development, enabling a deeper understanding of MCL's cellular origins and heterogeneity.
Targeting the epigenetic modifier KDM5 shows preclinical activity in mantle cell lymphoma, identifying a novel therapeutic vulnerability for potential future treatments.
Single-cell analysis reveals the HSP90-MYC-CDK9 network drives sequential BTKi and CAR-T resistance, suggesting co-targeting HSP90 and CDK9 as a novel strategy for dual-refractory MCL.
This preclinical study identifies that the miR-17-92 cluster suppresses the tumor suppressor BTG2, leading to B-cell receptor signaling overactivation and suggesting BTG2 as a prognostic biomarker.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
PLSCR1 induction by retinoic acid/interferon-α enhances immunogenic cell death in MCL, improving the efficacy of dendritic cell-based vaccines by boosting anti-tumor T-cell responses in vitro.
This preclinical study identifies the protease SENP3 as a novel driver of MCL proliferation via the Wnt10a signaling pathway, presenting SENP3 as a potential new therapeutic target.
Preclinically, chlorambucil and ibrutinib show synergistic apoptosis in an MCL cell line, suggesting a novel chemo-BTKi combination strategy potentially mediated by inhibiting the AKT signaling pathway.
The deubiquitinase USP35 stabilizes CXCR3 protein expression in MCL cells, promoting oncogenic signaling via JAK/STAT and c-Myc, identifying the USP35-CXCR3 axis as a novel therapeutic target.
Upregulation of the mTOR pathway drives acquired resistance to PRMT5 inhibitors in preclinical MCL models; combining with an mTOR inhibitor like temsirolimus overcomes this resistance and improves survival.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
A preclinical prostate cancer model shows Bortezomib resistance is driven by autophagy induction and reduced oxidative stress, suggesting potential combination strategies with autophagy inhibitors for MCL.
This review identifies the lncRNA LINK-A as an upregulated oncogene in MCL, presenting it as a potential biomarker and therapeutic target involved in oncogenic pathways and therapy resistance.
A novel SRC-3 inhibitor, SI-10, demonstrates preclinical efficacy in ibrutinib-resistant MCL models, identifying SRC-3 as a potential therapeutic target to overcome BTKi resistance.
This review identifies the lncRNA ROR1-AS1 as a pro-oncogenic factor in mantle cell lymphoma, suggesting it may serve as a novel biomarker or therapeutic target.
This preclinical study identifies a novel STAT5B-DCAF13-p53/xCT pathway that suppresses ferroptosis to promote MCL progression, revealing ferroptosis induction as a potential new therapeutic strategy.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
Magnetic Resonance Spectroscopy (MRS) can non-invasively detect metabolic changes, like lactate and alanine, offering an early biomarker to predict response or resistance to BTK inhibitors in MCL.
A novel 7-gene signature linked to ferroptosis predicts overall survival in MCL, identifying high-risk patients and suggesting potential new therapeutic targets like the MEK inhibitor Trametinib.